NORTH CHICAGO, Ill., June 7, 2022 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced it will present data from its migraine portfolio at the 2022 American Headache Society (AHS) Annual Scientific Meeting to be held in Denver, June 9-12. A total of 29 abstracts, including two oral presentations and one late-breaker presentation, will cover a wide range of studies across AbbVie’s migraine portfolio, and highlight the company’s newest migraine treatment, atogepant (QULIPTA).

Original Source

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219